Lu Si
Impact in
- Oncology top 0.5%
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 2%
- Immunotherapy and Immune Responses
Papers in
- Oncology 106
- Cutaneous Melanoma Detection and Management 66
- Cancer Immunotherapy and Biomarkers 31
- CAR-T cell therapy research 25
- Immunology 26
- Immunotherapy and Immune Responses 18
- Co-authors
- Jun Guo (81 shared papers)Xinan Sheng (89 shared papers)Chuanliang Cui (86 shared papers)Zhihong Chi (80 shared papers)Lili Mao (62 shared papers)Yan Kong (49 shared papers)Jie Dai (54 shared papers)Bin Lian (59 shared papers)
- Journals
- Annals of Oncology (15 papers)European Journal of Cancer (14 papers)Clinical Cancer Research (10 papers)BMC Cancer (8 papers)Journal for ImmunoTherapy of Cancer (6 papers)
- Partner nations
- ChinaEthiopiaUnited States
In The Last Decade
Lu Si
247 papers receiving 6.7k citations
Lu Si's Hit Papers
Peers
Comparison fields: 5 of 142
- Oncology 3.6k
- Immunology 1.1k
- Cancer Research 627
- Molecular Biology 2.4k
- Ophthalmology 195
Countries citing papers authored by Lu Si
This map shows the geographic impact of Lu Si's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Si with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Si more than expected).
Fields of papers citing papers by Lu Si
This network shows the impact of papers produced by Lu Si. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Si. The network helps show where Lu Si may publish in the future.
Co-authors
The 25 scholars most cited alongside Lu Si, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 253 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification Hit paper breakdown → | 2011 | 560 |
| 2 | 2011 | 305 | |
| 3 | Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Hit paper breakdown → | 2020 | 241 |
| 4 | 2019 | 240 | |
| 5 | 2011 | 210 | |
| 6 | 2011 | 206 | |
| 7 | 2018 | 161 | |
| 8 | 2019 | 146 | |
| 9 | 2013 | 146 | |
| 10 | 2021 | 143 | |
| 11 | 2014 | 142 | |
| 12 | 2019 | 131 | |
| 13 | 2016 | 122 | |
| 14 | 2021 | 116 | |
| 15 | 2019 | 114 | |
| 16 | 2013 | 93 | |
| 17 | 2017 | 85 | |
| 18 | 2019 | 82 | |
| 19 | 2021 | 81 | |
| 20 | 2017 | 80 |
About Lu Si
Lu Si is a scholar working on Oncology, Immunology, Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 253 papers that have together received 6.8k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (66 papers), Melanoma and MAPK Pathways (43 papers), Cancer Immunotherapy and Biomarkers (31 papers), CAR-T cell therapy research (25 papers), Immunotherapy and Immune Responses (18 papers), Optical Polarization and Ellipsometry (12 papers), Renal cell carcinoma treatment (10 papers) and Bladder and Urothelial Cancer Treatments (9 papers). The work is most often cited by research in Oncology (3.6k citations), Immunology (1.1k citations), Cancer Research (627 citations), Molecular Biology (2.4k citations) and Ophthalmology (195 citations). Lu Si has collaborated with scholars based in China, Ethiopia and United States. Frequent co-authors include Jun Guo, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Lili Mao, Yan Kong, Jie Dai, Bin Lian, Bixia Tang and Xieqiao Yan. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Clinical Cancer Research, BMC Cancer and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.